CN103509118A - 胰岛素-Fc融合蛋白 - Google Patents
胰岛素-Fc融合蛋白 Download PDFInfo
- Publication number
- CN103509118A CN103509118A CN201210198941.1A CN201210198941A CN103509118A CN 103509118 A CN103509118 A CN 103509118A CN 201210198941 A CN201210198941 A CN 201210198941A CN 103509118 A CN103509118 A CN 103509118A
- Authority
- CN
- China
- Prior art keywords
- insulin
- regular insulin
- fusion rotein
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract description 4
- 108020001507 fusion proteins Proteins 0.000 title abstract description 4
- 102000004877 Insulin Human genes 0.000 claims abstract description 30
- 108090001061 Insulin Proteins 0.000 claims abstract description 30
- 230000004927 fusion Effects 0.000 claims description 50
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108010075254 C-Peptide Proteins 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 21
- 229940125396 insulin Drugs 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000003746 Insulin Receptor Human genes 0.000 description 13
- 108010001127 Insulin Receptor Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004026 insulin derivative Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical group CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210198941.1A CN103509118B (zh) | 2012-06-15 | 2012-06-15 | 胰岛素-Fc融合蛋白 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210198941.1A CN103509118B (zh) | 2012-06-15 | 2012-06-15 | 胰岛素-Fc融合蛋白 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103509118A true CN103509118A (zh) | 2014-01-15 |
CN103509118B CN103509118B (zh) | 2016-03-23 |
Family
ID=49892585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210198941.1A Active CN103509118B (zh) | 2012-06-15 | 2012-06-15 | 胰岛素-Fc融合蛋白 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103509118B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016161983A1 (zh) * | 2015-04-10 | 2016-10-13 | 中国医学科学院药物研究所 | 一种融合载体蛋白及其在促进目的蛋白或多肽表达中的应用 |
WO2016133372A3 (ko) * | 2015-02-17 | 2016-10-13 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
WO2016178905A1 (en) | 2015-05-07 | 2016-11-10 | Eli Lilly And Company | Fusion proteins |
EP3127923A4 (en) * | 2014-03-31 | 2018-04-18 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
WO2018107117A1 (en) | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
WO2020006529A1 (en) | 2018-06-29 | 2020-01-02 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
WO2020096190A1 (ko) * | 2018-11-07 | 2020-05-14 | 제주대학교 산학협력단 | C-펩타이드를 유효성분으로 포함하는 미세먼지에 대한 피부보호용 화장료 조성물 |
WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
WO2021022149A1 (en) | 2019-07-31 | 2021-02-04 | Eli Lilly And Company | Insulin analogs and methods of using the same |
CN112316118A (zh) * | 2019-12-25 | 2021-02-05 | 沣潮医药科技(上海)有限公司 | Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途 |
US11168109B2 (en) | 2012-03-08 | 2021-11-09 | Hanmi Science Co., Ltd. | Process for preparation of physiologically active polypeptide complex |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
US11213581B2 (en) | 2020-04-10 | 2022-01-04 | Akston Biosciences Corporation | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use |
CN113968911A (zh) * | 2020-07-24 | 2022-01-25 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11434271B2 (en) | 2011-11-04 | 2022-09-06 | Hanmi Science Co., Ltd. | Method for preparing physiologically active polypeptide complex |
CN115894720A (zh) * | 2023-01-16 | 2023-04-04 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
WO2023086980A1 (en) | 2021-11-15 | 2023-05-19 | Eli Lilly And Company | Preserved formulations |
US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008019368A2 (en) * | 2006-08-07 | 2008-02-14 | Teva Biopharmaceuticals Usa, Inc. | Albumin-insulin fusion proteins |
WO2011053763A2 (en) * | 2009-10-30 | 2011-05-05 | Centocor Ortho Biotech Inc. | Il-17a antagonists |
CN102070717A (zh) * | 2009-11-19 | 2011-05-25 | 东莞太力生物工程有限公司 | 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物 |
CN102256992A (zh) * | 2008-12-19 | 2011-11-23 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
-
2012
- 2012-06-15 CN CN201210198941.1A patent/CN103509118B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008019368A2 (en) * | 2006-08-07 | 2008-02-14 | Teva Biopharmaceuticals Usa, Inc. | Albumin-insulin fusion proteins |
CN102256992A (zh) * | 2008-12-19 | 2011-11-23 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
WO2011053763A2 (en) * | 2009-10-30 | 2011-05-05 | Centocor Ortho Biotech Inc. | Il-17a antagonists |
CN102070717A (zh) * | 2009-11-19 | 2011-05-25 | 东莞太力生物工程有限公司 | 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物 |
Non-Patent Citations (1)
Title |
---|
NIRANJANA,K.R.P.,ET AL.: "ACCESSION NO:AEV43323.1,Fc IgG1 heavy chain constant region,partial[Homo sapiens]", 《GENBANK DATABASE》, 11 December 2011 (2011-12-11) * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11434271B2 (en) | 2011-11-04 | 2022-09-06 | Hanmi Science Co., Ltd. | Method for preparing physiologically active polypeptide complex |
US11168109B2 (en) | 2012-03-08 | 2021-11-09 | Hanmi Science Co., Ltd. | Process for preparation of physiologically active polypeptide complex |
AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
EP3127923A4 (en) * | 2014-03-31 | 2018-04-18 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
EP3889185A3 (en) * | 2014-03-31 | 2022-01-26 | Hanmi Pharm. Co., Ltd. | Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage |
WO2016133372A3 (ko) * | 2015-02-17 | 2016-10-13 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
WO2016161983A1 (zh) * | 2015-04-10 | 2016-10-13 | 中国医学科学院药物研究所 | 一种融合载体蛋白及其在促进目的蛋白或多肽表达中的应用 |
TWI656132B (zh) * | 2015-05-07 | 2019-04-11 | 美商美國禮來大藥廠 | 融合蛋白 |
US10709766B2 (en) | 2015-05-07 | 2020-07-14 | Eli Lilly And Company | Fusion proteins |
JP2018515088A (ja) * | 2015-05-07 | 2018-06-14 | イーライ リリー アンド カンパニー | 融合タンパク質 |
KR102059736B1 (ko) * | 2015-05-07 | 2019-12-26 | 일라이 릴리 앤드 캄파니 | 융합 단백질 |
CN107531806B (zh) * | 2015-05-07 | 2022-06-07 | 伊莱利利公司 | 融合蛋白 |
EA039770B1 (ru) * | 2015-05-07 | 2022-03-11 | Эли Лилли Энд Компани | Слитый белок для лечения сахарного диабета |
US11253574B2 (en) | 2015-05-07 | 2022-02-22 | Eli Lilly And Company | Fusion proteins and methods of use |
US12059452B2 (en) | 2015-05-07 | 2024-08-13 | Eli Lilly And Company | Fusion proteins |
CN107531806A (zh) * | 2015-05-07 | 2018-01-02 | 伊莱利利公司 | 融合蛋白 |
US9855318B2 (en) | 2015-05-07 | 2018-01-02 | Eli Lilly And Company | Fusion proteins |
WO2016178905A1 (en) | 2015-05-07 | 2016-11-10 | Eli Lilly And Company | Fusion proteins |
JP7170332B2 (ja) | 2016-12-09 | 2022-11-14 | アクストン バイオサイエンシズ コーポレーション | インスリンとfcの融合物および使用方法 |
US20190315828A1 (en) * | 2016-12-09 | 2019-10-17 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
US11359001B2 (en) | 2016-12-09 | 2022-06-14 | Akston Biosciences Corporation | Insulin-Fc fusions and methods of use |
JP2020503889A (ja) * | 2016-12-09 | 2020-02-06 | アクストン バイオサイエンシズ コーポレーションAkston Biosciences Corporation | インスリンとfcの融合物および使用方法 |
EP3551209A4 (en) * | 2016-12-09 | 2020-06-03 | Akston Biosciences Corporation | INSULIN FC FUSIONS AND METHOD FOR USE |
WO2018107117A1 (en) | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
AU2017371217B2 (en) * | 2016-12-09 | 2020-03-19 | Akston Biosciences Corporation | Insulin-Fc fusions and methods of use |
CN110612112B (zh) * | 2016-12-09 | 2024-03-29 | 阿卡斯通生物科学公司 | 胰岛素-fc融合物及使用方法 |
CN110612112A (zh) * | 2016-12-09 | 2019-12-24 | 阿卡斯通生物科学公司 | 胰岛素-fc融合物及使用方法 |
US10597435B2 (en) | 2016-12-09 | 2020-03-24 | Akston Biosciences Corporation | Insulin-Fc fusions and methods of use |
JP2023017806A (ja) * | 2016-12-09 | 2023-02-07 | アクストン バイオサイエンシズ コーポレーション | インスリンとfcの融合物および使用方法 |
EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
US10961294B2 (en) | 2018-06-29 | 2021-03-30 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
EP4344738A3 (en) * | 2018-06-29 | 2024-05-22 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
US11673934B2 (en) | 2018-06-29 | 2023-06-13 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
EP4186920A1 (en) * | 2018-06-29 | 2023-05-31 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
EP3892628A1 (en) | 2018-06-29 | 2021-10-13 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
CN113038964A (zh) * | 2018-06-29 | 2021-06-25 | 阿卡斯通生物科学公司 | 超长效胰岛素-fc融合蛋白及使用方法 |
US11773151B2 (en) | 2018-06-29 | 2023-10-03 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US10947292B2 (en) | 2018-06-29 | 2021-03-16 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US10851147B2 (en) | 2018-06-29 | 2020-12-01 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11261229B2 (en) | 2018-06-29 | 2022-03-01 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
EP3655006A4 (en) * | 2018-06-29 | 2021-01-13 | Akston Biosciences Corporation | ULTRAL LONG ACTING INSULIN-FC FUSION PROTEINS AND METHOD OF USE |
WO2020006529A1 (en) | 2018-06-29 | 2020-01-02 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
US10870686B2 (en) | 2018-06-29 | 2020-12-22 | Akston Biosciences Corporation | Ultra-long acting insulin-FC fusion proteins and methods of use |
EP4011908A1 (en) * | 2018-06-29 | 2022-06-15 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
WO2020096190A1 (ko) * | 2018-11-07 | 2020-05-14 | 제주대학교 산학협력단 | C-펩타이드를 유효성분으로 포함하는 미세먼지에 대한 피부보호용 화장료 조성물 |
WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
WO2021022149A1 (en) | 2019-07-31 | 2021-02-04 | Eli Lilly And Company | Insulin analogs and methods of using the same |
US11919935B2 (en) | 2019-12-24 | 2024-03-05 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
CN112316118B (zh) * | 2019-12-25 | 2022-08-09 | 沣潮医药科技(上海)有限公司 | Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途 |
CN112316118A (zh) * | 2019-12-25 | 2021-02-05 | 沣潮医药科技(上海)有限公司 | Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途 |
US11707517B2 (en) | 2020-04-10 | 2023-07-25 | Akston Biosciences Corporation | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
US11213581B2 (en) | 2020-04-10 | 2022-01-04 | Akston Biosciences Corporation | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use |
US11814418B2 (en) | 2020-04-10 | 2023-11-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
CN113968911B (zh) * | 2020-07-24 | 2023-10-10 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
CN113968911A (zh) * | 2020-07-24 | 2022-01-25 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
WO2022017309A1 (zh) | 2020-07-24 | 2022-01-27 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
WO2023086980A1 (en) | 2021-11-15 | 2023-05-19 | Eli Lilly And Company | Preserved formulations |
CN115894720A (zh) * | 2023-01-16 | 2023-04-04 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
CN115894720B (zh) * | 2023-01-16 | 2024-07-09 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
WO2024152787A1 (zh) * | 2023-01-16 | 2024-07-25 | 中国科学院上海药物研究所 | 一种长效胰岛素-Fc融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
CN103509118B (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103509118B (zh) | 胰岛素-Fc融合蛋白 | |
US12037393B2 (en) | P116 antibodies | |
WO2019174603A1 (zh) | 靶向ctla-4抗体、其制备方法和用途 | |
JP6313712B2 (ja) | 新生児Fc受容体への結合を強化された変異型Fcポリペプチド | |
US12077594B2 (en) | IL2RG binding molecules and methods of use | |
CN106687478B (zh) | 新的抗人Tie-2抗体 | |
CN111647082A (zh) | 抗人il-4ra的抗体及其用途 | |
CN105263961A (zh) | 用于预防、诊断或者治疗癌症或血管发生相关疾病的抗vegf抗体和含有所述抗体的药物组合物 | |
US20180298078A1 (en) | Method for producing fusion protein having igg fc domain | |
WO2022032025A1 (en) | Ifngr binding synthetic cytokines and methods of use | |
US20240166754A1 (en) | Il12rb1-binding molecules and methods of use | |
CN111363040A (zh) | 抗ox40的单克隆抗体及其应用 | |
US20230279127A1 (en) | Il12 receptor synthetic cytokines and methods of use | |
CN106018822A (zh) | 基于特异性单克隆或多克隆抗体建立的ny-eso-1抗原检测方法 | |
CN108456252B (zh) | 高特异性的抗兔IgG天然构象单克隆抗体 | |
EP4403571A1 (en) | Human epidermal growth factor receptor binding molecule and use thereof | |
US20230279125A1 (en) | Il28ra binding molecules and methods of use | |
US12018085B2 (en) | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases | |
CN117843802B (zh) | 串联抗体及其下游产品和应用 | |
CN117843805B (zh) | 抗体分子、核酸分子、药物组合物以及应用 | |
CN113004407B (zh) | Lag3抗体及其应用 | |
US20230391891A1 (en) | Il28a receptor binding synthetic cytokines and methods of use | |
KR20230042291A (ko) | Fgfr1/klb 표적화 효능작용 항원-결합 단백질 및 그와 glp-1r 효능작용 펩티드의 접합체 | |
TW202313685A (zh) | 抗人血清白蛋白的抗原結合蛋白 | |
US20230365696A1 (en) | Ifngr1 binding molecules and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: 201203 Shanghai City, Pudong New Area hi tech Bing Road No. 301 Patentee after: Shanghai metech junao Biological Technology Co. Ltd. Address before: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399 Patentee before: Guo Huaizu |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Insulin-Fc fusion protein Effective date of registration: 20190322 Granted publication date: 20160323 Pledgee: Shanghai Baimai Pharmaceutical Co.,Ltd. Pledgor: Shanghai metech junao Biological Technology Co. Ltd. Registration number: 2019310000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210119 Granted publication date: 20160323 Pledgee: Shanghai Biomabs Pharmaceuticals Co.,Ltd. Pledgor: SHANGHAI MAITAI JUNAO BIOTECHNOLOGY Co.,Ltd. Registration number: 2019310000007 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |